Court Opinion

ID: 6104562
Source: CourtListenerOpinion
Date Created: 2022-01-19 16:03:27.2301+00
Date Added: 2024-06-11T08:53:44.751033
License: Public Domain

Third District Court of Appeal
                               State of Florida

                       Opinion filed January 19, 2022.
       Not final until disposition of timely filed motion for rehearing.

                            ________________

                             No. 3D20-0985
                        Lower Tribunal No. 20-3662
                           ________________

                  Javier Alonso-Llamazares, M.D.,
                                  Appellant,

                                     vs.

         International Dermatology Research, Inc., etc.,
                                  Appellee.

     An Appeal from a non-final order from the Circuit Court for Miami-Dade
County, Valerie R. Manno Schurr, Judge.

      Ainsworth + Clancy, PLLC, and Janna O. Mateo and Ryan M. Clancy,
for appellant.

     Feiler & Leach, P.L., and Martin E. Leach, for appellee.

Before HENDON, MILLER and LOBREE, JJ.

     LOBREE, J.

     This appeal stems from a non-compete agreement entered into
between appellant Javier Alonso-Llamazares, M.D. (“Dr. Alonso”) and his

former employer, appellee International Dermatology Research Inc. (“IDR”).

After IDR terminated Dr. Alonso’s employment, IDR sought, and was

granted, a temporary injunction enforcing the parties’ non-compete

agreement. We affirm the trial court’s determination that the non-compete

agreement was enforceable and the requirements for a temporary injunction

were established, but reverse and remand for the trial court to describe in

reasonable detail the act or acts restrained as required by Florida Rule of

Civil Procedure 1.610(c).

      Background Facts and Procedural History

      IDR is a medical practice management business that utilizes

dermatologists to conduct clinical research projects in the area of

dermatology. On October 4, 2011, IDR and Dr. Alonso entered into an

Agreement for Management Services and Clinical Research Services (the

“Agreement”).    Under the Agreement, IDR agreed to provide certain

management services to Dr. Alonso’s dermatological medical practice. Dr.

Alonso, in turn, agreed to conduct clinical research projects for and on behalf

of IDR.   Because this case concerns interpretation of the terms of the

Agreement, relevant sections are set forth at length below. Section 3 of the

Agreement is entitled “Term” and provides in relevant part as follows:

                                      2
      Unless terminated earlier pursuant to Section 11 of this
      Agreement, the term of engagement under this Agreement shall
      be for a period of two (2) year [sic] commencing on the Effective
      Date and ending on the first anniversary of the Effective Date
      (the “Term”).

Section 11 of the Agreement, entitled “Termination,” provides in part as

follows:

      11.1 Termination by Company. Company shall be entitled to
      terminate this Agreement, upon written notice to Physician, at
      any time for any or no reason.

      11.2 Termination by Physician. . . .

      11.3 Effects of Termination. Upon the termination of this
      Agreement:

             (a) Physician’s duties and Company’s obligations shall
      cease as of the effective date of termination, provided, however,
      that the Physician shall in all events of termination be responsible
      for arranging for the smooth transition of Physician’s duties to
      appropriate employees or contractors of Company and all duties
      and obligations of Physician intended to survive termination shall
      survive (including Physician’s obligations under Sections 8, 9.9,
      12 and 13 of this Agreement).

(emphasis in original). Dr. Alonso also agreed to a non-compete provision

in section 12 of the Agreement that required the following:

      12.    Non-Competition      and    Confidentiality.   Physician
      acknowledges that incident to Physician’s engagement,
      Physician will gain extensive and valuable experience and
      knowledge relating to Company and the Company’s business
      and will have access to confidential information relating to the
      business and operations of Company, the use or disclosure of
      which would cause Company substantial loss and damages that
      would not be readily calculated and for which no remedy at law

                                       3
would be adequate. Accordingly, as a material inducement to
Company’s entering into this Agreement, Physician hereby
covenants as follows:

      12.1 Non-Competition. During the Term of this
Agreement and thereafter for a period of two (2) years (the
''Post-Term Restrictive Period") from the date of expiration
or termination of the Term of this Agreement for any reason
whatsoever, Physician shall not directly or indirectly, on
Physician’s own behalf or as a principal, partner, member,
shareholder, officer, employee, agent, consultant, contractor,
physician, director or trustee of any person, partnership, firm,
association, corporation, hospital, clinic or other medical facility:
(i) engage in the practice of medicine anywhere within a two (2)
mile radius of the Premises provided by the Company for the
operation of the Practice; (ii) perform, conduct, promote, market,
exploit, participate in, engage in or otherwise be involved with, or
engage in any business that directly or indirectly performs,
conducts, promotes, markets, exploits or engages in or is
otherwise involved in, clinical research or trials relating to
dermatology including, without limitation, dermatological
products or procedures, anywhere within a five (5) mile radius of
the Premises provided by the Company for the operation of the
Practice; (iii) attempt to solicit or solicit or otherwise contact the
patients, customers or clients (including any pharmaceutical
companies or manufacturers) of Company or other physician
practices managed by Company or use patient or customer lists
developed or owned by Company or other physician practices
managed by Company; or (iv) divert or attempt to divert from
Company or other physician practices managed by Company
any business or business opportunity whatsoever or accept any
business from any patients, customers or clients (including any
pharmaceutical companies or manufacturers) of Company or
other physician practices managed by Company; provided that,
Physician may conduct any clinical studies that are not the same
as or similar to the types of studies conducted by the Company
(as determined by the Company), provided Physician first
obtains the Company’s written consent to each such study. . . .

      12.2 Confidentiality of Patient and Client Information. . . .

                                  4
            12.3 Enforcement. Physician acknowledges and agrees
     that irreparable injury will result to Company in the event of
     Physician’s breach of any covenant set forth in this Section 12,
     that a material inducement to Company’s engagement of
     Physician is the covenants set forth in Section 12, and that
     monetary damages in an action at law would not provide an
     adequate remedy in the event of a breach of this Section 12.
     Physician further acknowledges and agrees that the covenants
     contained in Section 12 are necessary for the protection of
     Company’s legitimate business and professional duties, ethical
     obligations, and interest, and are reasonable in scope and
     content and have been negotiated in good faith and on an arms-
     length basis. In the event of Physician’s breach or threatened
     breach of Section 12, this Section may be enforced by the
     obtaining of an injunction to restrain the violation thereof by
     Physician.

          12.4 Survival. The covenants of this Section 12 shall
     survive the expiration or termination of this Agreement.

(bold emphasis added) The parties continued their relationship when the

Agreement expired in 2013. On January 4, 2016, the parties executed an

Amendment to Agreement (the “First Amendment”), modifying provisions of

the Agreement, including that the Term of the engagement under the

Agreement is through December 31, 2016. The First Amendment also

stated that all other aspects of the Agreement remained in effect, including

section 12. Then, on January 4, 2017, the parties executed a Second

Amendment to Agreement (the “Second Amendment”).              The Second

Amendment provided that “the term of the engagement under this

Agreement shall be through December 31, 2017 (the ‘Term’).” As with the

                                     5
First Amendment, apart from other modifications made by the Second

Amendment, the Agreement remained in effect, including but not limited to

section 12.    Finally, on June 1, 2017, the parties executed the Third

Amendment to Agreement (the “Third Amendment”). The Third Amendment

made changes to Dr. Alonso’s hours and compensation but did not modify

the Term. The Third Amendment also provided that “[i]n all other respects,

the Agreement, the First Amendment and the Second Amendment remain in

full force and effect, including, but not limited to, Section 12-Non-Competition

and Confidentiality.”

      Dr. Alonso continued to work for IDR after December 31, 2017.

Subsequently, IDR notified Dr. Alonso by letter that “as of November 1, 2019,

your services are no longer required at [IDR].”1 Dr. Alonso then began

operating Driven Research LLC on January 2, 2020. Dr. Alonso does not

dispute that he began Driven Research to conduct clinical trials and that as

of January 2, 2020, he was competing with IDR.

      Shortly thereafter, on February 12, 2020, IDR filed suit against Dr.

Alonso, seeking temporary and permanent injunctions and asserting claims

for breach of contract and tortious interference with contractual relations

1
  Although the letter is undated, the parties stipulated that IDR “terminated
[Dr. Alonso’s] employment on November 1, 2019, through a written letter.”

                                       6
based on Dr. Alonso’s active competition against IDR.        IDR moved for

emergency injunctive relief, arguing that Dr. Alonso breached section 12 of

the Agreement by competing with IDR and soliciting IDR’s customers and

clients. IDR argued that it was entitled to an injunction because section

542.335(1)(j), Florida Statutes (2017), 2 provides that irreparable harm is

presumed when a party establishes the violation of an enforceable restrictive

covenant. IDR also asserted that it did not have an adequate remedy at law.

IDR argued that it had a likelihood of success on the merits because the

Agreement contained an enforceable non-compete provision and further

argued that the granting of a temporary injunction was not against the public

interest because public policy favors the enforcement of contracts and non-

compete agreements, as evidenced by section 542.335. IDR sought to

enjoin Dr. Alonso from: (1) working with Driven Research; (2) directly or

indirectly competing with IDR for a period of two years; (3) being involved in

clinical research or trials relating to dermatological products or procedures

2
  A non-compete provision “is governed by the statute existing when it was
executed.” White v. Mederi Caretenders Visiting Servs. of Se. Fla., LLC, 226
So. 3d 774, 777 n.1 (Fla. 2017). Here, the Third Amendment, which stated
that “[i]n all other respects, the Agreement, the First Amendment and the
Second Amendment remain in full force and effect, including, but not limited
to, Section 12-Non-Competition and Confidentiality,” was entered into in
2017. As noted in White, there have been no amendments to section
542.335 since its enactment in 1996. Id.

                                      7
for a period of two years within a five-mile radius; (4) attempting to solicit or

soliciting or contacting IDR’s patients, customers, or clients for a period of

two years; (5) using patient or customer lists developed by IDR. IDR also

demanded that Dr. Alonso to turn over any of IDR’s confidential information

in his possession.

      Dr. Alonso responded that IDR did not have a likelihood of success on

the merits because the post-term restrictive period was not in effect on

January 2, 2020, when he began working for Driven Research. Specifically,

Dr. Alonso argued that the Agreement expired on December 31, 2017,

“meaning that the Restrictive Covenant would be in full force and effect for

two years from the end of the Term (December 31, 2019).” Thus, Dr. Alonso

asserted, “[t]he expiration date for the Non-Compete clause is December 31,

2019,” and he was not in breach of the non-compete provision when he

began working for Driven Research. Dr. Alonso denied soliciting IDR’s

clients, but stated that even if he had, this was permissible because the non-

compete provision had expired. Dr. Alonso further argued that IDR could not

show irreparable harm because after December 31, 2019, he was free to

compete with IDR. As to whether the public interest would be served by

granting an injunction, Dr. Alonso stated that the public interest would not be

                                       8
served by enforcing an expired contract and that enjoining medical research

“for the most part” is not in the public interest.

      The trial court held an evidentiary hearing to address IDR’s motion.

IDR argued that the non-compete provision was reasonable in length and

geographic limitation. IDR also asserted that the non-compete provision was

in effect on January 2, 2020, because section 12.4 of the Agreement

provides that “[t]he covenants of this Section 12 shall survive the expiration

or termination of this Agreement.” Under section 12.4, the non-compete

provision survived the expiration of the Agreement and the two-year period

of restraint was then triggered on November 1, 2019, when IDR terminated

Dr. Alonso’s employment in accordance with section 11.1. In response, Dr.

Alonso argued that the non-compete provision was not valid because under

the clear language of the Agreement, the Agreement expired on December

31, 2017, and the non-compete provision lasts for two years thereafter,

ending on December 31, 2019. Dr. Alonso maintained that reading section

12.1 and 12.4 together, the non-compete restraints in 12.1 survive for only

two years after expiration of the term of the Agreement.

      At the hearing, the trial court heard testimony from Dr. Alonso and

Silvia Trinidad (“Trinidad”), the president and CEO of IDR. Trinidad testified

that prior to working with IDR, Dr. Alonso had not worked in clinical trials that

                                        9
were regulated by the FDA, and that IDR trained him in that area. IDR also

paid for Dr. Alonso to attend conferences to introduce him to and foster his

relationship with pharmaceutical companies and contract research

organizations. 3 Significantly, Trinidad also testified that Dr. Alonso had sent

a letter to one of IDR’s clients in which he requested work from that client

and for the client to visit him. Trinidad testified that Dr. Alonso obtained a list

of IDR’s clients, patients and subjects for trials, contract research

organizations, and the prices IDR charges for studies it conducts. Trinidad

asserted that Dr. Alonso obtained this information through IDR employees

who he “took from IDR” and are working for him. Trinidad also testified that

former patients of IDR had called IDR to make appointments for a study Dr.

Alonso was conducting after they were contacted by someone at Dr.

Alonso’s office who had previously worked at IDR. On cross-examination,

Trinidad acknowledged that while at IDR, Dr. Alonso did not have access to

a computer containing the list of patients or prices.

      Dr. Alonso testified that prior to working at IDR, he had been involved

in two clinical studies. He also testified that when he worked at IDR, and

now at Driven Research, he does not have access to a patient database.

3
  Trinidad explained that contract research organizations are a liaison
between pharmaceutical companies and researchers.

                                        10
On cross-examination, Dr. Alonso admitted that he is competing with IDR. 4

      The trial court granted IDR’s motion for a temporary injunction. First,

the trial court found that the non-compete provision was enforceable. The

trial court found that the provision was supported by three legitimate

business interests: (1) valuable confidential business information; (2)

substantial relationships with specific prospective or existing customers; and

(3) specialized training. The trial court further found that Dr. Alonso “failed

to assert any sufficient challenge to the geographic scope or the duration of

the Non-Compete Agreement, or the scope of activity prohibited by it.” As

to Dr. Alonso’s argument that the non-compete provision had expired, the

trial court found that under section 12.4, the non-compete provision survived

the expiration of the Agreement where Dr. Alonso continued to work at IDR.

      Second, the trial court determined that the requirements for a

temporary injunction had been satisfied. The trial court found that: (1) IDR

will continue to suffer immediate and irreparable harm if Dr. Alonso is not

prohibited from additional breaches and Dr. Alonso did not rebut the statutory

presumption of irreparable harm under section 542.335(1)(j); (2) IDR has a

substantial likelihood of success on its claim that Dr. Alonso breached

4
 Dr. Alonso stated, “First of all, I’m not competing with the plaintiff only. I’m
competing with every clinical researcher in Miami.”

                                       11
section 12 of the Agreement; (3) IDR did not have an adequate remedy at

law; and (4) the temporary injunction will further the public interest in IDR’s

ability to protect its investment in its own business information and Dr.

Alonso made no showing that a specific public policy requirement

substantially outweighed the need to protect IDR’s legitimate business

interest.

      Dr. Alonso moved for reconsideration and, in the alternative, for a stay

pending review, reasserting his argument that he was not subject to the non-

compete provision on January 2, 2020, because it expired on December 31,

2019. In support of his motion for stay pending review, Dr. Alonso attached

an affidavit stating that Driven Research will be in non-compliance with the

FDA if he does not oversee the research and that patients could be left

without proper medical supervision unless a stay is issued. After a hearing,

the trial court denied Dr. Alonso’s motion for reconsideration and deferred

ruling on the stay. Dr. Alonso’s appeal from the trial court’s order granting a

temporary injunction and the denial of his motion for reconsideration

followed. 5

5
   We have jurisdiction to review the non-final order granting the temporary
injunction under Florida Rule of Appellate Procedure 9.130(a)(3)(B).
Because the order denying Dr. Alonso’s motion for reconsideration was
entered and appealed within 30 days from the entry of the temporary

                                      12
      Standard of Review

      “The standard of review of trial court orders on requests for temporary

injunctions is a hybrid. To the extent the trial court’s order is based on factual

findings, we will not reverse unless the trial court abused its discretion;

however, any legal conclusions are subject to de novo review.” Gainesville

Woman Care, LLC v. State, 210 So. 3d 1243, 1258 (Fla. 2017) (quoting Fla.

High Sch. Athletic Ass’n v. Rosenberg ex rel. Rosenberg, 117 So. 3d 825,

826 (Fla. 4th DCA 2013)); accord Fla. Dep’t of Health v. Florigrown, LLC,

317 So. 3d 1101, 1110 (Fla. 2021) (“We review a trial court’s factual findings

on the[] elements [of a claim for a temporary injunction] for competent,

substantial evidence, and we review its legal conclusions de novo. To the

extent the decision to enter a temporary injunction involves an exercise of

discretion, we defer to the trial court unless it has abused its discretion.”

(citation omitted)); see also Briceño v. Bryden Invs., Ltd., 973 So. 2d 614,

616 (Fla. 3d DCA 2008) (“A trial court has wide discretion to grant or deny a

temporary injunction and an appellate court will not interfere with the

exercise of such discretion unless the party challenging the grant or denial

clearly shows an abuse of that discretion.”(quoting Perry & Co. v. First Sec.

injunction, that order is also properly on review. Panama City Gen. P’ship v.
Godfrey Panama City Inv., LLC, 109 So. 3d 291, 291 (Fla. 1st DCA 2013).

                                       13
Ins. Underwriters, Inc., 654 So. 2d 671, 671 (Fla. 3d DCA 1995))). “An

appellant who challenges the trial court’s order on a motion for temporary

injunction has a heavy burden; the trial court’s ruling is presumed to be

correct and can only be reversed where it is clear the court abused its

discretion.” Atomic Tattoos, LLC v. Morgan, 45 So. 3d 63, 64 (Fla. 2d DCA

2010).

      Analysis

      To obtain a temporary injunction, a party must establish “(1) a

substantial likelihood of success on the merits, (2) the unavailability of an

adequate remedy at law, (3) irreparable harm absent entry of an injunction,

and (4) that the injunction would serve the public interest.” Florigrown, LLC,

317 So. 3d at 1110.6 Relevant here, section 542.335(1)(j), Florida Statutes,

provides that a court shall enforce a valid “restrictive covenant by any

appropriate and effective remedy, including, but not limited to, temporary and

permanent injunctions.” See also Ansaarie v. First Coast Cardiovascular

Inst., P.A., 252 So. 3d 287, 290 (Fla. 1st DCA 2018) (“A temporary injunction

is an available remedy when a party establishes that it has a valid,

enforceable restrictive covenant that was violated.”). Further, “[t]he violation

6
 We affirm without discussion Dr. Alonso’s challenge that the elements for
a temporary injunction were not satisfied here.

                                      14
of an enforceable restrictive covenant creates a presumption of irreparable

injury to the person seeking enforcement of a restrictive covenant.” §

542.335(1)(j).

      To be enforceable, a restrictive covenant must be reasonable with

regard to “time, area, and line of business” and “set forth in a writing signed

by the person against whom enforcement is sought.” § 542.335(1)(a).

Additionally, “[i]n Florida, a contract providing restrictions on competition

must involve a legitimate business interest as defined by statute to be

enforceable.” White, 226 So. 3d at 779; see § 542.335(1)(b), Fla. Stat.

(stating that “[t]he person seeking enforcement of a restrictive covenant shall

plead and prove the existence of one or more legitimate business interests

justifying the restrictive covenant” and providing non-exhaustive list of

legitimate business interests). “[T]he determination of whether an activity

qualifies as a protected legitimate business interest under the statute is

inherently a factual inquiry, which is heavily industry—and context-specific.”

White, 226 So. 3d at 786. A party seeking a temporary injunction also must

“plead and prove that the contractually specified restraint is reasonably

necessary to protect the legitimate business interest or interests justifying

the restriction.” § 542.335(1)(c). Once a party establishes a prima facie case

that the restriction is reasonably necessary, “the person opposing

                                      15
enforcement has the burden of establishing that the contractually specified

restraint is overbroad, overlong, or otherwise not reasonably necessary to

protect the established legitimate business interest or interests.” Id. Finally,

the statute provides that courts must construe restrictive covenants “in favor

of providing reasonable protection to all legitimate business interests

established by the person seeking enforcement,” and without application of

“any rule of contract construction that requires the court to construe a

restrictive covenant narrowly, against the restraint, or against the drafter of

the contract.” § 542.335(1)(h).

      On appeal, Dr. Alonso argues that the trial court erred in finding that

the non-compete provision was valid and enforceable.          Specifically, Dr.

Alonso asserts that the non-compete provision expired before he began

working for Driven Research and that the trial court abused its discretion in

finding that the non-compete provision was supported by a legitimate

business interest. Neither of Dr. Alonso’s arguments is persuasive.

      Dr. Alonso contends that because the Agreement and its Amendments

expired on December 31, 2017, section 12.1’s non-compete provision ended

on December 31, 2019, which was “two (2) years (the ‘Post-Term Restrictive

Period’) from the date of expiration or termination of the Term of this

Agreement.” Thus, Dr. Alonso claims he was free to begin working for Driven

                                      16
Research, unrestrained by the non-compete provision, on January 2, 2020,

two months after his November 1, 2019, termination from IDR. Given the

plain language of the Agreement, we disagree with Dr. Alonso.

     “This Court has held that post-termination restrictions expire upon the

termination of an agreement for a specific term, even if an employee remains

an at-will employee after the term of the written agreement expires.” Zupnik

v. All Fla. Paper, Inc., 997 So. 2d 1234, 1238 (Fla. 3d DCA 2008). This

principle applies where the restrictive covenant provides that it applies

following termination of employment and the parties’ agreement does not

expressly provide that the covenant survives the expiration of the

employment contract. See id. (holding that where non-compete provision

applied “during the [two-year] Employment Term and within twelve (12)

months from the termination of said term” and parties’ agreement did not

“contain language specifying that the restrictive covenants would continue

beyond the two-year term if [employee]” continued working, non-compete

provision expired at end of two-year employment term even where employee

continued working beyond that point); Sanz v. R.T. Aerospace Corp., 650

So. 2d 1057, 1059 (Fla. 3d DCA 1995) (reversing preliminary injunction in

favor of employer where restrictive covenants applied “during the existence

of [employee’s] employment and for a period of twenty-four (24) months

                                    17
immediately following the termination of his employment” and employee

continued to work for employer after employment agreement expired

because covenants “were only applicable if [employee] terminated his

employment . . . during the life of the written agreement”). If, however, an

employment agreement contains express language showing that the parties

intend for a non-compete provision to survive the expiration or termination of

the agreement, the provision remains effective where the agreement expires

but the employment relationship continues. See St. Johns Inv. Mgmt. Co. v.

Albaneze, 22 So. 3d 728, 732 (Fla. 1st DCA 2009) (finding that language in

contract showed that parties intended non-compete provision to survive

employee’s post-term employment); Brenner v. Barco Chems. Div., Inc., 209

So. 2d 277, 278 (Fla. 3d DCA 1968) (affirming decree restraining employee

who resigned 18 months after contract expired where non-compete provision

applied during term of employment “and for a period of one year immediately

following the Expiration or termination of such employment by mutual

agreement” and contract provided that it would govern parties’ relations if

employee was retained by employer after expiration of contract); Sanz, 650

So. 2d at 1059 (rejecting appellee’s argument that non-compete covenants

survived expiration of agreement because “the fact that the noncompete

clauses were independent of other covenants in the agreement does not

                                     18
mean that they survived the expiration of the contract in the absence of an

express provision to that effect” (emphasis added)); cf. Century 21 Real Est.

of S. Fla., Inc. v. Braun & May Realty, Inc., 706 So. 2d 878, 879 (Fla. 3d DCA

1997) (holding that termination triggered provision in agreement requiring

commission payments even though agreement had expired because “the

agreements provided that the parties continued to be bound by the

agreement terms”). Here, section 12.4 of the Agreement provides as follows:

“Survival. The covenants of this Section 12 shall survive the expiration or

termination of this Agreement.” Given the above principles, we conclude that

the express language of section 12.4 shows that the parties intended the

non-compete provision contained in section 12.1 to remain effective after the

Agreement’s expiration. 7 Thus, the non-compete provision survived the

December 31, 2017, expiration and was triggered upon IDR’s termination of

Dr. Alonso’s employment on November 19, 2019.

      Dr. Alonso insists that this Court’s opinion in Brenner, 209 So. 2d at

277, holds that in order for a non-compete provision to survive post-term, the

contract must also expressly state that its terms apply if the employee

7
  Dr. Alonso asserts that section 12.4 applies only to sections 12.2 and 12.3,
serving to “extend out” those sections, which do not contain two-year
limitations. Section 12.4, however, states that it applies to “[t]he covenants
of this Section.”

                                     19
continues to work for the employer after expiration of the contract. Brenner

makes no such holding. In Brenner, the parties’ contract “provided for non

competition by Brenner ‘during the term of his employment by company and

for a period of one year immediately following the Expiration or termination

of such employment by mutual agreement.’” Id. at 278. The contract also

provided that “[i]n case the services of SALES MANAGER (Brenner) are

retained by COMPANY after the expiration of this contract without formal

contract, it is hereby mutually agreed that the terms of this contract shall

continue to govern the relations between COMPANY and SALES

MANAGER.” Id. Brenner continued to work for his employer after the

contract between the parties expired, but eventually resigned. This Court

affirmed the trial court’s decree restraining him from competing with his

former employer for one year after his resignation. In reaching its holding,

Brenner contains little analysis, only distinguishing between the non-

compete at issue, which applied following the expiration or termination of

employment, with the non-compete at issue in Storz Broadcasting Co. v.

Courtney, 178 So. 2d 40, 41 n.2 (Fla. 3d DCA 1965), which applied “upon

termination of his employment with the Company.” This Court’s conclusion

did not rest on a finding that where a contract, like here, expressly provides

that the non-compete covenants survive expiration or termination, the

                                     20
contract must also state that its terms apply after expiration if the employee

continues to work for the employer. Even so, it is clear based on the

language of the Agreement that the parties contemplated continued

employment by Dr. Alonso. Section 12.4 states that the covenants in section

12 “survive the expiration or termination of this Agreement.” Section 12.1, in

contrast, uses the phrase “termination of the Term of this Agreement.”

(emphasis added). Termination of the Term of the Agreement is December

31, 2017. If, in the survival provision, section 12.4, the parties had intended

the covenants to survive only as measured from December 31, 2017, they

would have used the phrase, “termination of the Term of this Agreement,” as

they did in section 12.1. See Beach Towing Servs., Inc. v. Sunset Land

Assocs., LLC, 278 So. 3d 857, 861 (Fla. 3d DCA 2019) (stating that “[a]s a

general proposition, the use of different language in different contractual

provisions strongly implies that a different meaning was intended” (quoting

Fowler v. Gartner, 89 So. 3d 1047, 1048 (Fla. 3d DCA 2012))). Moreover,

the use of the word termination in section 12.4 refers to section 11 of the

Agreement, entitled “Termination.” Notably, section 11.1 states that IDR

“shall be entitled to terminate this Agreement, upon written notice to

Physician, at any time for any or no reason.” (emphasis added). Additionally,

section 11.3, entitled, “Effects of Termination” includes a provision that “all

                                      21
duties and obligations of Physician intended to survive termination shall

survive (including Physician’s obligations under Sections . . . 12 . . . of this

Agreement).” Giving effect to all portions of the Agreement and reading it as

a whole, as we must, see Massey Servs., Inc. v. Sanders, 312 So. 3d 209,

214 (Fla. 5th DCA 2021); Anarkali Boutique, Inc. v. Ortiz, 104 So. 3d 1202,

1205–06 (Fla. 4th DCA 2012), we find that the Agreement “contemplated a

situation wherein [Dr. Alonso] remained a[n] [IDR] employee in the absence

of a written agreement.” St. Johns, 22 So. 3d at 733.

      Dr. Alonso contends that even if the non-compete provision was in

effect on January 2, 2020, the trial court abused its discretion in finding that

a legitimate business interest justified the non-compete provision. 8 Section

8
   Dr. Alonso briefly argues that IDR failed to present evidence that the non-
compete provision was reasonable in area and line of business. See §
542.335(1), Fla. Stat. He asserts that as a result, IDR failed to establish a
prima facie case and the burden never shifted to him to establish that the
provision was overbroad or unreasonable under section 542.335(1)(c). A
claim that IDR did not establish a prima facie case is a challenge to the
sufficiency of the evidence. Dr. Alonso did not argue below that IDR failed
to make a prima facie case that the provision was reasonable as to area and
line of business, and we will not address the argument for the first time on
review. F.B. v. State, 852 So. 2d 226, 229 (Fla. 2003) (“In general, to raise
a claimed error on appeal, a litigant must object at trial when the alleged error
occurs. ‘Furthermore, in order for an argument to be cognizable on appeal,
it must be the specific contention asserted as legal ground for the objection,
exception, or motion below.’” (citation omitted) (quoting Steinhorst v. State,
412 So. 2d 332, 338 (Fla.1982))). Although the sufficiency of the evidence
may be raised on appeal absent preservation by objection or motion below
under Florida Rule of Civil Procedure 1.530(e), that rule applies to judgments

                                       22
542.335(1)(b) sets forth a non-exhaustive list of legitimate business interests

that may justify the restrictive covenant sought to be enforced. See White,

226 So. 3d at 783 (“The statute defines legitimate business interests through

a non-exhaustive list.”). Here, the trial court found that IDR demonstrated a

legitimate business interest in “substantial relationships with specific

prospective or existing customers.” See § 542.335(1)(b)(3) (stating that

“legitimate business interests” includes “[s]ubstantial relationships with

specific prospective or existing customers, patients, or clients”). Dr. Alonso

argues that because he testified that he did not have access to a patient

database at IDR, and Trinidad testified that the names of patients are

confidential and patients are referred to by initials, there was no evidence

presented below to prove the existence of a substantial relationship with

identifiable “specific prospective or existing customers, patients, or clients.”

This argument is without merit. First, the trial court did not find that IDR

proved the existence of a legitimate business interest in substantial

relationships with specific prospective or existing patients, but rather,

entered after civil non-jury trials. See Winchel v. PennyMac Corp., 222 So.
3d 639, 644 (Fla. 2d DCA 2017) (stating that under plain language of rule
1.530(e) “when there has been a nonjury trial and the appellate issue is the
sufficiency of the evidence to support the judgment, the failure to object
based on the insufficiency of the evidence will not bar raising that issue on
appeal”).

                                      23
customers. The finding that IDR had substantial relationships with existing

customers was supported by Trinidad’s testimony that Dr. Alonso had mailed

a letter to IDR’s client requesting work.9 Dr. Alonso acknowledged on cross-

examination that he sent the letter.       “‘[T]he right to prohibit the direct

solicitation of existing customers’ is a legitimate business interest, and a

covenant not to compete which includes a non-solicitation clause is

breached when a former employee directly solicits customers of his former

employer.” Atomic Tattoos, LLC, 45 So. 3d at 65 (quoting Dyer v. Pioneer

Concepts, Inc., 667 So. 2d 961, 964 (Fla. 2d DCA 1996)). There is also no

requirement that IDR present evidence of a particular, identifiable existing

customer, client, or patient with which it has a substantial relationship. See

Ansaarie, 252 So. 3d at 290–91 (holding that trial court properly found

hospital demonstrated legitimate business interest in its substantial

relationships with existing patients when it put forth evidence that “a number

of its patients had recently requested to transfer their files to [former

employee/doctor]” and distinguishing its prior holding in University of Florida,

Board of Trustees v. Sanal, 837 So. 2d 512, 516 (Fla. 1st DCA 2003), that a

legitimate business relationship with a prospective patient “must be, in

addition to ‘substantial,’ one with a particular, identifiable, individual”).

9
    The parties use the terms “client” and “customer” interchangeably.

                                      24
Because the non-compete provision was in effect when Dr. Alonso began

working for Driven Research, and IDR established as least one legitimate

business interest, 10 the trial court did not err in finding the non-compete

provision valid and enforceable. 11

      Dr. Alonso also argues that the temporary injunction is facially deficient

because it does not set forth the act or acts from which he is restrained as

required by Florida Rule of Civil Procedure 1.610(c). On this point, we agree

with Alonso. Rule 1.610(c) provides that an injunction “shall describe in

reasonable detail the act or acts restrained without reference to a pleading

or another document.”     “A temporary injunction requires strict compliance

with Florida Rule of Civil Procedure 1.610.” Coscia v. Old Fla. Plantation,

10
   Although Dr. Alonso also challenges on appeal the trial court’s finding that
the non-compete provision was supported by legitimate business interests in
valuable confidential business information and specialized training, we need
not address these arguments because section 542.335(1)(b) requires only
that the restrictive covenant be supported by “one or more legitimate
business interests.”
11
   We note that IDR was required under section 542.335(1)(c) to also “plead
and prove that the contractually specified restraint is reasonably necessary
to protect the legitimate business interest or interests justifying the
restriction.” Here, the trial court found that the non-compete provision was
reasonably necessary to protect IDR’s legitimate business interests. On
appeal, Dr. Alonso does not challenge the trial court’s finding that the non-
compete provision was “reasonably necessary,” other than to claim that the
burden to establish that the restraint is “overbroad, overlong, or otherwise
not reasonably necessary” never shifted to him. See supra note 7.

                                      25
Ltd., 828 So. 2d 488, 490 (Fla. 2d DCA 2002). With regard to prohibited

conduct, “[o]ne against whom an injunction is directed should not be left in

doubt as to what he is required to do.” 12 Clark v. Allied Assocs., Inc., 477

So. 2d 656, 658 (Fla. 5th DCA 1985). Here, the trial court failed to set forth

in reasonable detail the act or acts Dr. Alonso is enjoined from performing.

Indeed, the temporary injunction does not actually enjoin any activity by Dr.

Alonso. IDR responds that Dr. Alonso knows what conduct is impermissible

because IDR “sought only to enjoin Dr. Alonso from being involved in clinical

research trials related to dermatology.” In support of its argument, IDR cites

to Trinidad’s testimony at the evidentiary hearing. 13       But rule 1.610(c)

12
   Relatedly, an injunction may not be enforced by contempt where its terms
are not clear and definite. See Osmo Tec SACV Co. v. Crane Env’t, Inc.,
884 So. 2d 324, 326–27 (Fla. 2d DCA 2004) (“Corollary to the requirement
that enjoined acts be described ‘in reasonable detail’ is the rule that a
contempt sanction may not be imposed for the violation of an injunction
unless the purportedly contemptuous act clearly contravenes the injunction.
Moreover, ‘[a]n essential finding to support contempt is the party’s intent to
violate the court order at issue.’” (citation omitted) (quoting Merrill Lynch Tr.
Co. v. Alzheimer’s Lifeliners Ass’n, 832 So. 2d 948, 954 (Fla. 2d DCA
2002))); see also Penzell v. M & M Constr. Grp. Corp., 915 So. 2d 194, 196
(Fla. 3d DCA 2005) (“When an injunction is sufficiently clear and definite to
apprise the parties of the court’s mandate, the parties must comply or face
the penalty of contempt.”); Tarantola v. Henghold, 233 So. 3d 508, 510 (Fla.
1st DCA 2017).
13
     On direct examination, Trinidad testified as follows:
        Q: As I – ma’am, as I read your agreement, it only prohibits him
        related to dermatological studies; is that correct?
        A: Yes.

                                       26
expressly prohibits “reference to a pleading or another document” to

determine the requirements of the temporary injunction. (emphasis added).

Moreover, IDR’s assertion is contradicted by its motion for emergency

injunctive relief, which alleged that Dr. Alonso breached the non-compete

provision when he competed with IDR and solicited IDR’s customers, and

sought a temporary injunction enjoining, among other things, Dr. Alonso from

“attempt[ting] to solicit or solicit or otherwise contact the patients, customers

or clients (including any pharmaceutical companies or manufactures [sic] of

Plaintiff.”14

        Q: So if he wants to do a COVID-19 one, he’s free to do that, isn’t
        he?
        A: Yes.
        Q: He -- if he wants to do -- get a Botox practice going, he’s free
        to do that, correct?
        A: Yes.
        Q: There’s only a very limited restriction in what he is not allowed
        to do and that is basically to do dermatological studies; is that
        correct?
        MR. CLANCY: Objection --
        A: To do clinical trials in dermatology.
14
     In pertinent part, IDR sought to enjoin Dr. Alonso from the following acts:
        3. Enjoin Defendant for a period of two (2) years not to directly
        or indirectly, on Defendant’s own behalf or as a principal partner,
        member, shareholder, officer, employee, agent, consultant,
        contractor, physician, director or trustee of any person
        partnership, firm association, corporation, hospital, clinic or other
        medical facility, engage, perform, conduct, promote, market,
        exploit indirectly performs, conducts, promotes, markets, exploits
        or engage in or is otherwise involved in, clinical research or trials

                                         27
      Accordingly, we reverse the temporary injunction in part with directions

to the trial court to “describe in reasonable detail the act or acts restrained.”

Fla. R. Civ. P. 1.610(c); see also Angelino v. Santa Barbara Enters., LLC, 2

So. 3d 1100, 1104 (Fla. 3d DCA 2009) (finding temporary injunction

defective under rule 1.610(c) where temporary injunction enjoined plaintiff

from “competing against [defendant]” and “usurping [defendant’s] business

opportunities, customers, and suppliers”); Dickerson v. Senior Home Care,

Inc., 181 So. 3d 1228, 1229 (Fla. 5th DCA 2015) (reversing temporary

injunction as facially deficient and remanding for further proceedings where,

among other things, “the trial court’s order does not comply with rule 1.610(c)

because it simply enjoins Appellants ‘from violating their Non–Compete,

Non–Disclosure, Non–Solicitation Agreements’”). We otherwise affirm the

temporary injunction entered below.

      Affirmed in part, reversed in part, and remanded.

      relating to dermatological including, without limitations,
      dermatological products or procedures, anywhere within five (5)
      mile radius of the premises provided by the Plaintiff for the
      operation of Defendant’s business, attempt to solicit or solicit or
      otherwise contact the patients, customers or clients (including
      any pharmaceutical companies or manufactures) of Plaintiff or
      other physician practices managed by Plaintiff or use patient or
      customer lists developed or owned by Plaintiff or other
      physicians practices managed by Plaintiff.

                                       28